microRNA therapy is a good option for heart disease
A new study published in the journal PLOS ONE describes a novel nuclear acting microRNA, which might be a new option for the treatment of ischemic cardiovascular disease, according to researchers from the University of Eastern Finland.
This novel microRNA, miR-466c, has a different mechanism of action and it upregulates the vascular endothelial growth factor A (VEGFA) by targeting the gene promoter in the cell nucleus.
These observations suggest that miR-466c regulates VEGFA gene transcription in the nucleus by targeting the promoter and expands on our understanding of the role of miRNAs well beyond their canonical role.
In addition to expanding the understanding of microRNA, these findings have commercial relevance for the development of novel RNA drugs. In fact, RNA activation as a phenomenon has been known for 16 years already, but its commercial potential has been recognized only recently.
Also, RNatives is developing engineered exosomes for the delivery of these RNAs into patients. Rnatives is a gene therapy company utilizing the novel biology of nuclear microRNAs to modulate gene expression of desired target genes (VEGFA gene).
ارسال به دوستان